Breeze Holdings Acquisition Corp. (BREZW) operates as a blank check company, or special purpose acquisition company (SPAC), whose primary business is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, with a focus on the defense technology industry; it offers no current products or services beyond its SPAC structure for capital raising and deployment into acquisition targets. Incorporated in 2020 and headquartered in Irving, Texas, the company functions as a subsidiary of Breeze Sponsor, LLC and trades warrants on Nasdaq under the BREZW ticker, targeting investors seeking exposure to private companies entering public markets through SPAC transactions. In a major strategic shift, Breeze completed a business combination with Taiwan-based YD Biopharma Limited in August 2025, following shareholder approval on August 14, 2025, and an initial merger agreement announced in September 2024 with subsequent amendments; the combined entity now operates as YD Bio Limited, trading ordinary shares and warrants on Nasdaq under the symbols YDES and YDESW, with an estimated enterprise value of nearly $700 million, shifting focus to biopharmaceuticals including innovative vaccines, therapeutic biologics for infectious diseases, cancer prevention diagnostics such as methylation detection for pancreatic cancer, exosome-based therapeutics, ophthalmology cellular drugs, and clinical testing supply for partners like Novartis. Prior to this merger, Breeze terminated a planned combination with TV Ammo, Inc. in August 2024 and began trading on OTCQX under BRZH, BRZHR, and BRZHW, while actively pursuing targets with a deadline extended to December 26, 2024. Geographically, the post-merger operations emphasize Taiwan-based development and manufacturing with global market aspirations via Nasdaq listing.